Short answers, pulled from the story.
Leo Sternbach accidentally synthesized the first benzodiazepine, chlordiazepoxide, in 1955 while working at Hoffmann-La Roche. He set the compound aside untested, and it was rediscovered in April 1957 by co-worker Earl Reeder during a lab clean-up. Animal testing revealed strong sedative, anticonvulsant, and muscle relaxant effects, leading to its introduction under the brand name Librium in 1960.
Benzodiazepines are prescribed for anxiety disorders, panic disorder, generalized anxiety disorder, insomnia, seizures, alcohol withdrawal, muscle spasms, and as a premedication before surgery or dental procedures. They are also used in acute psychiatric emergencies such as agitation, acute psychosis, and mania, and for certain sleep disorders such as rapid eye movement behavior disorder.
Benzodiazepines bind to a specific site on the GABAA receptor and act as positive allosteric modulators, increasing the frequency with which the receptor's chloride ion channel opens when the neurotransmitter GABA is already bound. The resulting influx of chloride ions hyperpolarizes the neuron, making it less likely to fire and producing sedative, anxiolytic, anticonvulsant, and muscle-relaxant effects.
Long-term benzodiazepine use carries risks of tolerance, physical dependence, and a withdrawal syndrome that can include seizures and delirium. Multiple studies have found that benzodiazepines are not significantly more effective than placebo for sleep over the long term, and their use is associated with cognitive impairment, increased dementia risk, depression, and elevated mortality in people aged 65 or younger when co-prescribed with opioids.
Benzodiazepine withdrawal syndrome involves rebound symptoms and new symptoms including insomnia, tremors, agitation, and in severe cases, seizures and delirium tremens. The American Society of Addiction Medicine issued guidance in June 2025 recommending dose reductions of 5 to 10% every 2-4 weeks, with a maximum taper rate of 25% every two weeks. Diazepam is the preferred drug for managing withdrawal because it has the longest half-life of all benzodiazepines.
The American Geriatrics Society lists all benzodiazepines as potentially inappropriate medications for older adults in the Beers List. Elderly patients face doubled rates of traffic accidents and falls, increased risk of hip fractures, and cognitive effects that can mimic dementia or depression. Long-term use progressively worsens over time in this group, and adverse effects on cognition may be misattributed to aging rather than to the medication.